This week’s clinical pharmacology highlights include advances in cancer therapy, long-term followup of the landmark PROACT trial comparing anticoagulation strategies after aortic replacement, and the finding that hydrocortisone may not reduce mortality in septic shock.
The US FDA has approved the antihelminthic drug moxidectin (developed by Medicines Development for Global Health) for the treatment of onchocerciasis.¹
Merck’s ivermectin, developed in the late 1970s, is the only other pharmaceutical agent approved for treating onchocerciasis. Moxidectin has outperformed ivermectin in clinical trials, demonstrating superior efficacy and comparable safety. Continue reading “Moxidectin, First New Treatment for River Blindness in 30 Years, Approved by FDA”
This week’s clinical pharmacology highlights include a new treatment for river blindness, further success for JAK inhibitors in inflammatory diseases, and the finding that more patients are taking medications associated with depressive symptoms.
Alprazolam is a short-acting benzodiazepine medication used in the treatment of anxiety disorders. It acts as a positive allosteric modulator of synaptic GABAA receptors, increasing neuronal hyperpolarization and CNS depressant effects. Alprazolam is the only benzodiazepine with significant antidepressant efficacy.